SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Stuart A Scott, Aniwaa Owusu Obeng, Jean-Sébastien Hulot, Antiplatelet drug interactions with proton pump inhibitors, Expert Opinion on Drug Metabolism & Toxicology, 2014, 10, 2, 175

    CrossRef

  2. 2
    J P Depta, P A Lenzini, D E Lanfear, T Y Wang, J A Spertus, R G Bach, S Cresci, Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction, The Pharmacogenomics Journal, 2014,

    CrossRef

  3. 3
    Jean-Philippe Collet, Jean-Sébastien Hulot, Jérémie Abtan, Ghalia Anzaha, Mathieu Kerneis, Johanne Silvain, Guillaume Cayla, Stephen A. O’Connor, Olivier Barthélémy, Farzin Beygui, Sophie Galier, Delphine Brugier, Eric J. Stanek, Scott L. Charland, Vanessa Gallois, Gilles Montalescot, Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study, European Journal of Clinical Pharmacology, 2014, 70, 9, 1049

    CrossRef

  4. 4
    Trina Huynh, Andrea Backes, Kelly Lee, Joseph Ma, Grace Kuo, Handbook of Personalized Medicine, 2014,

    CrossRef

  5. 5
    Mustapha M. El-Halabi, Nathalie Zgheib, Nabil M. Mansour, Ahmad Malli, Ola A. Ghaith, Rami Mahfouz, Samir Alam, Ala I. Sharara, CYP2C19 Genetic Polymorphism, Rabeprazole and Esomeprazole Have no Effect on the Antiplatelet Action of Clopidogrel, Journal of Cardiovascular Pharmacology, 2013, 62, 1, 41

    CrossRef

  6. 6
    Christian Funck-Brentano, Jean Szymezak, Olivier Steichen, Dominique Ducint, Mathieu Molimard, Véronique Remones, Michel Azizi, Pascale Gaussem, Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers, Archives of Cardiovascular Diseases, 2013, 106, 12, 661

    CrossRef

  7. 7
    Payman Shahabi, Gérard Siest, Bernard Herbeth, Daniel Lambert, Christine Masson, Jean-Sébastien Hulot, Sébastien Bertil, Pascale Gaussem, Sophie Visvikis-Siest, Influence of Genetic Variations on Levels of Inflammatory Markers of Healthy Subjects at Baseline and One Week after Clopidogrel Therapy; Results of a Preliminary Study, International Journal of Molecular Sciences, 2013, 14, 8, 16402

    CrossRef

  8. 8
    J. Szymezak, P. Gaussem, Inhibiteurs de la pompe à protons et clopidogrel (Plavix®) : une liaison dangereuse ?, La Revue de Médecine Interne, 2013, 34, 2, 99

    CrossRef

  9. 9
    Deepak Voora, Geoffrey S. Ginsburg, Clinical Application of Cardiovascular Pharmacogenetics, Journal of the American College of Cardiology, 2012, 60, 1, 9

    CrossRef

  10. 10
    Masato Ohbuchi, Kiyoshi Noguchi, Akio Kawamura, Takashi Usui, Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4, Xenobiotica, 2012, 42, 7, 633

    CrossRef

  11. 11
    S A Scott, S Martis, I Peter, Y Kasai, R Kornreich, R J Desnick, Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness, The Pharmacogenomics Journal, 2012, 12, 4, 297

    CrossRef

  12. 12
    N. Mallouk, C. Labruyere, J.-L. Reny, C. Chapelle, M. Piot, P. Fontana, J.-C. Gris, X. Delavenne, P. Mismetti, S. Laporte, Prevalence of poor biological response to clopidogrel, Thrombosis and Haemostasis, 2012, 107, 3, 494

    CrossRef

  13. 13
    Joan Chen, Yuhong Cathy Yuan, Grigorios I. Leontiadis, Colin W. Howden, Recent Safety Concerns With Proton Pump Inhibitors, Journal of Clinical Gastroenterology, 2012, 46, 2, 93

    CrossRef

  14. 14
    J.-S. Hulot, J.-P. Collet, G. Montalescot, Résistance au clopidogrel, tests génétiques et tests fonctionnels, Archives of Cardiovascular Diseases Supplements, 2012, 4, 3, 209

    CrossRef

  15. 15
    Jean-Sébastien Hulot, Jean-Philippe Collet, Gilles Montalescot, Genetic substudy of the PLATO trial, The Lancet, 2011, 377, 9766, 637

    CrossRef

  16. 16
    Jean-Philippe Collet, Jean-Sébastien Hulot, Ghalia Anzaha, Ana Pena, Thomas Chastre, Claire Caron, Johanne Silvain, Guillaume Cayla, Anne Bellemain-Appaix, Jean-Baptiste Vignalou, Sophie Galier, Olivier Barthélémy, Farzin Beygui, Vanessa Gallois, Gilles Montalescot, High Doses of Clopidogrel to Overcome Genetic Resistance, JACC: Cardiovascular Interventions, 2011, 4, 4, 392

    CrossRef

  17. 17
    Jean Szymezak, Caroline Moreau, Marie-Anne Loriot, Eric Durand, Hubert Van Viet, Michel Desnos, Pascale Gaussem, High on-clopidogrel platelet reactivity: Genotyping Can help to optimize antiplatelet treatment, Thrombosis Research, 2011, 128, 1, 92

    CrossRef

  18. 18
    Kengo Tsukahara, Kazuo Kimura, Satoshi Morita, Toshiaki Ebina, Masami Kosuge, Kiyoshi Hibi, Noriaki Iwahashi, Mitsuaki Endo, Nobuhiko Maejima, Teruyasu Sugano, Satoshi Umemura, Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects, Journal of Cardiology, 2011, 57, 3, 275

    CrossRef

  19. 19
    Loren Laine, Proton Pump Inhibitor Co-therapy With Clopidogrel: Is There GI Benefit or Cardiovascular Harm?, Gastroenterology, 2011, 140, 3, 769

    CrossRef

  20. 20
    Grigorios I. Leontiadis, Yuhong Yuan, Colin W. Howden, The Interaction Between Proton Pump Inhibitors and Clopidogrel and Upper Gastrointestinal Bleeding, Gastrointestinal Endoscopy Clinics of North America, 2011, 21, 4, 637

    CrossRef

  21. 21
    Thomas Cuisset, Corinne Frere, Pierre Julien Moro, Jacques Quilici, Coline Pons, Bénédicte Gaborit, Laurence Camoin, Pierre-Emmanuel Morange, Jean-Louis Bonnet, Marie-Christine Alessi, Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome, Thrombosis Research, 2010, 126, 5, e400

    CrossRef

  22. 22
    Jean-Philippe Collet, Gilles Montalescot, Jean-Sébastien Hulot, Genetics of the Response to Antithrombotic Drugs and the Need for Monitoring,